MX2020005041A - Agonistas parciales de interleucina-2. - Google Patents
Agonistas parciales de interleucina-2.Info
- Publication number
- MX2020005041A MX2020005041A MX2020005041A MX2020005041A MX2020005041A MX 2020005041 A MX2020005041 A MX 2020005041A MX 2020005041 A MX2020005041 A MX 2020005041A MX 2020005041 A MX2020005041 A MX 2020005041A MX 2020005041 A MX2020005041 A MX 2020005041A
- Authority
- MX
- Mexico
- Prior art keywords
- muteins
- interleukin
- partial agonists
- sub
- useful
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- C07K14/55—IL-2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/74—Inducing cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
En este documento se proporcionan, entre otras cosas, muteínas de interleucina 2 (IL-2) de humano o variantes de las mismas. En particular, en este documento se proporcionan muteínas de IL-2 que tienen una capacidad de unión disminuida para IL-2R?. Tales muteínas de IL-2 son útiles, por ejemplo, como agonista parcial de IL-2 en aplicaciones donde es útil la reducción o inhibición de una o más funciones de IL-2 y/o IL-15 (por ejemplo, en el tratamiento de enfermedades o afecciones autoinmunes). También se proporcionan ácidos nucleicos que codifican tales muteínas de IL-2, métodos para hacer tales muteínas de IL-2, composiciones farmacéuticas que incluyen tales muteínas de IL-2 y métodos de tratamiento utilizando tales composiciones farmacéuticas.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201762589497P | 2017-11-21 | 2017-11-21 | |
PCT/US2018/062122 WO2019104092A1 (en) | 2017-11-21 | 2018-11-20 | Partial agonists of interleukin-2 |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2020005041A true MX2020005041A (es) | 2020-10-12 |
Family
ID=66631137
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2020005041A MX2020005041A (es) | 2017-11-21 | 2018-11-20 | Agonistas parciales de interleucina-2. |
Country Status (13)
Country | Link |
---|---|
US (2) | US20200299349A1 (es) |
EP (1) | EP3713592A4 (es) |
JP (2) | JP7464278B2 (es) |
KR (1) | KR20200086722A (es) |
CN (1) | CN111615396A (es) |
AU (2) | AU2018372167B2 (es) |
BR (1) | BR112020009920A2 (es) |
CA (1) | CA3082904A1 (es) |
IL (1) | IL274723A (es) |
MX (1) | MX2020005041A (es) |
RU (1) | RU2020120145A (es) |
SG (1) | SG11202004581PA (es) |
WO (1) | WO2019104092A1 (es) |
Families Citing this family (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA3056630A1 (en) | 2017-03-15 | 2018-09-20 | Pandion Therapeutics, Inc. | Targeted immunotolerance |
KR20200010354A (ko) | 2017-05-24 | 2020-01-30 | 팬디온 테라퓨틱스, 인코포레이티드 | 표적화된 면역관용 |
MX2020001332A (es) | 2017-08-03 | 2020-09-09 | Synthorx Inc | Conjugados de citoquina para el tratamiento de enfermedades proliferativas e infecciosas. |
US10174091B1 (en) | 2017-12-06 | 2019-01-08 | Pandion Therapeutics, Inc. | IL-2 muteins |
US10946068B2 (en) | 2017-12-06 | 2021-03-16 | Pandion Operations, Inc. | IL-2 muteins and uses thereof |
DE202019005887U1 (de) | 2018-07-03 | 2023-06-14 | Marengo Therapeutics, Inc. | Anti-TCR-Antikörpermoleküle und Verwendungen davon |
WO2020236875A1 (en) | 2019-05-20 | 2020-11-26 | Pandion Therapeutics, Inc. | Madcam targeted immunotolerance |
CN110642934B (zh) * | 2019-09-10 | 2022-08-23 | 中国医学科学院北京协和医院 | 靶向调节t细胞的长效白介素-2及其在治疗自身免疫病中的应用 |
WO2021127487A2 (en) | 2019-12-20 | 2021-06-24 | Regeneron Pharmaceuticals, Inc. | Novel il2 agonists and methods of use thereof |
US11633488B2 (en) | 2020-01-10 | 2023-04-25 | Bright Peak Therapeutics Ag | Modified IL-2 polypeptides and uses thereof |
AU2021207901A1 (en) | 2020-01-14 | 2022-09-08 | Synthekine, Inc. | IL2 orthologs and methods of use |
CN115362168A (zh) * | 2020-01-14 | 2022-11-18 | 辛德凯因股份有限公司 | 偏向化il2突变蛋白方法和组合物 |
US11981715B2 (en) | 2020-02-21 | 2024-05-14 | Pandion Operations, Inc. | Tissue targeted immunotolerance with a CD39 effector |
WO2021253360A1 (en) * | 2020-06-18 | 2021-12-23 | Proviva Therapeutics (Hong Kong) Limited | Activatable procytokines |
MX2023010926A (es) * | 2021-03-31 | 2023-09-27 | Hanmi Pharmaceutical Co Ltd | Novedoso conjugado de analogo de il-2 inmunoestimulante y procedimiento de preparacion del mismo. |
EP4366782A1 (en) | 2021-07-09 | 2024-05-15 | Bright Peak Therapeutics AG | Conjugates of checkpoint inhibitors with il-2, and uses thereof |
CA3224147A1 (en) | 2021-07-09 | 2023-01-12 | Vijaya Raghavan PATTABIRAMAN | Antibody conjugates and manufacture thereof |
WO2023281482A1 (en) | 2021-07-09 | 2023-01-12 | Bright Peak Therapeutics Ag | Cd20-targeted il-2 and its uses |
US20240158537A1 (en) | 2021-07-09 | 2024-05-16 | Bright Peak Therapeutics Ag | Synthetic il-7 and il-7 immunocytokines |
US20240132563A1 (en) | 2022-02-23 | 2024-04-25 | Bright Peak Therapeutics Ag | Bifunctional cytokine compositions |
WO2023200796A1 (en) * | 2022-04-13 | 2023-10-19 | The Regents Of The University Of California | Immune cell inhibition by immune checkpoint engagers |
WO2024044716A2 (en) * | 2022-08-26 | 2024-02-29 | Sonoma Biotherapeutics, Inc. | Tethered interleukin-2 recombinant receptors and methods of use |
WO2024086739A1 (en) | 2022-10-20 | 2024-04-25 | Synthekine, Inc. | Methods and compositions of il12 muteins and il2 muteins |
WO2024150175A1 (en) | 2023-01-11 | 2024-07-18 | Bright Peak Therapeutics Ag | Conditionally activated proteins and methods of use |
WO2024150174A1 (en) | 2023-01-11 | 2024-07-18 | Bright Peak Therapeutics Ag | Conditionally activated immunocytokines and methods of use |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DZ2788A1 (fr) * | 1998-05-15 | 2003-12-01 | Bayer Ag | Agonistes et antagonistes selectifs à IL-2. |
TWI364295B (en) * | 2002-12-26 | 2012-05-21 | Mountain View Pharmaceuticals | Polymer conjugates of cytokines, chemokines, growth factors, polypeptide hormones and antagonists thereof with preserved receptor-binding activity |
RU2006135112A (ru) * | 2004-03-05 | 2008-04-10 | Чирон Корпорейшн (Us) | Тест-система in vitro для прогнозирования устойчивости пациента к терапевтическим средствам |
EP1846020B1 (en) * | 2005-01-27 | 2013-08-21 | Novartis Vaccines and Diagnostics, Inc. | Methods for treating renal cell carcinoma |
US8906356B2 (en) * | 2007-11-05 | 2014-12-09 | Massachusetts Institute Of Technology | Mutant interleukin-2 (IL-2) polypeptides |
KR102349549B1 (ko) * | 2010-11-12 | 2022-01-11 | 넥타르 테라퓨틱스 | Il-2 부분 및 중합체의 접합체 |
CA2860170C (en) * | 2010-12-22 | 2022-06-14 | The Board Of Trustees Of The Leland Stanford Junior University | Superagonists and antagonists of interleukin-2 |
BR112016018288A2 (pt) * | 2014-02-06 | 2017-10-10 | Hoffmann La Roche | proteínas de fusão de interleucina 2 e uso das mesmas |
CA2946398A1 (en) * | 2014-04-24 | 2015-10-29 | The Board Of Trustees Of The Leland Stanford Junior University | Superagonists, partial agonists and antagonists of interleukin-2 |
-
2018
- 2018-11-20 CN CN201880086929.7A patent/CN111615396A/zh active Pending
- 2018-11-20 SG SG11202004581PA patent/SG11202004581PA/en unknown
- 2018-11-20 AU AU2018372167A patent/AU2018372167B2/en active Active
- 2018-11-20 US US16/765,617 patent/US20200299349A1/en not_active Abandoned
- 2018-11-20 RU RU2020120145A patent/RU2020120145A/ru unknown
- 2018-11-20 WO PCT/US2018/062122 patent/WO2019104092A1/en unknown
- 2018-11-20 EP EP18881013.9A patent/EP3713592A4/en active Pending
- 2018-11-20 CA CA3082904A patent/CA3082904A1/en active Pending
- 2018-11-20 BR BR112020009920-1A patent/BR112020009920A2/pt unknown
- 2018-11-20 KR KR1020207017428A patent/KR20200086722A/ko not_active Application Discontinuation
- 2018-11-20 MX MX2020005041A patent/MX2020005041A/es unknown
- 2018-11-20 JP JP2020545077A patent/JP7464278B2/ja active Active
-
2020
- 2020-05-17 IL IL274723A patent/IL274723A/en unknown
-
2021
- 2021-05-13 US US17/320,174 patent/US20210269498A1/en active Pending
-
2024
- 2024-01-19 AU AU2024200355A patent/AU2024200355A1/en active Pending
- 2024-03-21 JP JP2024044912A patent/JP2024079749A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
EP3713592A1 (en) | 2020-09-30 |
BR112020009920A2 (pt) | 2020-12-15 |
EP3713592A4 (en) | 2022-01-12 |
KR20200086722A (ko) | 2020-07-17 |
AU2024200355A1 (en) | 2024-03-21 |
CN111615396A (zh) | 2020-09-01 |
RU2020120145A (ru) | 2021-12-22 |
AU2018372167A1 (en) | 2020-06-11 |
JP2024079749A (ja) | 2024-06-11 |
CA3082904A1 (en) | 2019-05-31 |
JP7464278B2 (ja) | 2024-04-09 |
IL274723A (en) | 2020-07-30 |
SG11202004581PA (en) | 2020-06-29 |
WO2019104092A1 (en) | 2019-05-31 |
US20200299349A1 (en) | 2020-09-24 |
AU2018372167B2 (en) | 2023-12-07 |
US20210269498A1 (en) | 2021-09-02 |
JP2021508252A (ja) | 2021-03-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2020005041A (es) | Agonistas parciales de interleucina-2. | |
NZ761434A (en) | Cytokine conjugates for the treatment of autoimmune diseases | |
CN106659757A8 (zh) | 白介素2的超级激动剂、部分激动剂和拮抗剂 | |
PH12020551261A1 (en) | Il-15 conjugates and uses thereof | |
MX2020012602A (es) | Composiciones bacterianas dise?adas y usos de las mismas. | |
NZ736560A (en) | Proteins specific for cd137 | |
MX2022007754A (es) | Nuevos agonistas de il2 y metodos de uso de estos. | |
MX2022005411A (es) | COMPUESTOS DE UNIÓN A IL-2RßYC. | |
MX2020014031A (es) | Proteinas heterodimericas y usos de las mismas. | |
PH12019500643A1 (en) | Antibodies that bind interleukin-2 and uses thereof | |
BR112017022349A2 (pt) | ?composto, composição, método, e, método para inibir uma proteína irak? | |
MX2022001061A (es) | Agentes de interleuquina-2 y usos de los mismos. | |
MX2010003574A (es) | Anticuerpos il-23. | |
CR20210500A (es) | Anticuerpos de cadena pesada que se unen al psma | |
EP3957723A3 (en) | Engineered ligase variants | |
MX2022002740A (es) | Conjugados de il-2 y metodos de uso para tratar enfermedades autoinmunes. | |
MX2020007945A (es) | Proteinas f del rsv estabilizadas y usos de las mismas. | |
MX2021015761A (es) | Polipeptidos. | |
PH12021551534A1 (en) | Antibody against human il-4ra and use thereof | |
WO2018042385A3 (en) | Methods and compositions involving interleukin-6 receptor alpha-binding single chain variable fragments | |
JOP20210326A1 (ar) | أجسام مضادة للمستقبل 1 لببتيد إدرار الصوديوم في البول وطرق استخدامها | |
MX2021005593A (es) | Miméticos de interleucina dividida y sus usos. | |
MX2020009733A (es) | Composiciones. | |
EP4032539A4 (en) | IMMUNOCYTOKINE WITH HETERODIMERIC PROTEIN COMPLEX BASED ON IL-15/IL-15R-ALPHA | |
EA201991951A1 (ru) | Низковязкие высококонцентрированные составы на основе эволокумаба и способы их получения |